Cencora, Inc. $COR Shares Sold by Ethic Inc.

Ethic Inc. trimmed its position in Cencora, Inc. (NYSE:COR) by 70.4% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,653 shares of the company’s stock after selling 15,836 shares during the period. Ethic Inc.’s holdings in Cencora were worth $2,079,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Baader Bank Aktiengesellschaft grew its position in shares of Cencora by 318.5% during the 2nd quarter. Baader Bank Aktiengesellschaft now owns 4,336 shares of the company’s stock valued at $1,300,000 after buying an additional 3,300 shares during the last quarter. Voleon Capital Management LP acquired a new position in Cencora in the first quarter valued at approximately $3,111,000. Focus Partners Wealth grew its holdings in shares of Cencora by 25.8% during the first quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock valued at $1,589,000 after purchasing an additional 1,171 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Cencora by 947.5% during the second quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after purchasing an additional 232,539 shares during the last quarter. Finally, Martin Capital Partners LLC raised its position in shares of Cencora by 205.2% during the 2nd quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock worth $1,135,000 after purchasing an additional 2,544 shares during the period. 97.52% of the stock is owned by institutional investors.

Cencora Price Performance

Shares of NYSE:COR opened at $338.07 on Friday. The stock has a market cap of $65.58 billion, a price-to-earnings ratio of 42.52, a PEG ratio of 1.61 and a beta of 0.66. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. Cencora, Inc. has a 12 month low of $223.92 and a 12 month high of $377.54. The stock’s 50 day moving average price is $349.47 and its 200 day moving average price is $316.22.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same period last year, the company posted $3.34 EPS. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is currently 30.19%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on COR. Robert W. Baird set a $392.00 price objective on Cencora in a research note on Tuesday, December 16th. TD Cowen boosted their price target on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. Evercore ISI set a $400.00 price objective on shares of Cencora and gave the stock an “outperform” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Finally, Wells Fargo & Company boosted their target price on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and an average target price of $373.25.

Insider Activity

In other news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares of the company’s stock, valued at $12,398,792. The trade was a 11.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the sale, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 20,317 shares of company stock worth $7,009,260. Corporate insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.